This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings-consensus: Archive
Wall Street Analysts Believe OppFi (OPFI) Could Rally 34.78%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 34.8% upside potential for OppFi (OPFI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OPFINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Onto Innovation (ONTO)? Wall Street Analysts Think 26.09%
by Zacks Equity Research
The mean of analysts' price targets for Onto Innovation (ONTO) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ONTONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Prelude Therapeutics (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PRLDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Freshworks (FRSH) Have the Potential to Rally 38.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38.4% in Freshworks (FRSH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
FRSHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CARLPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Globant (GLOB) Reports Next Week: What You Should Expect
by Zacks Equity Research
Globant (GLOB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GLOBNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NTLAPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Klarna (KLAR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Klarna (KLAR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KLARNegative Net Change PAGSNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Canada Goose (GOOS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Canada Goose (GOOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GOOSNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RNXTNegative Net Change PRMENegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate